HerAnova Lifesciences

Home
United States
Burlington, MA
HerAnova Lifesciences

We are advancing innovative women’s health solutions with a focus on endometriosis and infertility.

05/29/2026

Women's health has long faced critical unmet needs. At HerAnova, our mission is to help advance integrated care solutions designed to address those gaps.

Focused on endometriosis and female fertility, we are building a collaborative approach to innovation through internally developed and externally partnered diagnostics, therapeutics, and medical devices.

By integrating diagnostics, therapeutics, medical devices, and data analytics, HerAnova aims to provide a one-stop solution for unmet needs in obstetrics and gynecology.

Learn more about HerAnova: https://heranova.com/about-us/

05/26/2026

Endometriosis is more than a gynecologic condition; it can play an important role in fertility.

Did you know:
• Endometriosis may affect a substantial proportion of women experiencing fertility¹
• Diagnosis can be challenging and often relies on invasive procedures²
• Endometriosis may contribute to infertility and may impact IVF outcomes³

For patients and clinicians navigating fertility care, understanding potential underlying factors may help inform next steps. Greater awareness of endometriosis and its possible impact on reproductive health remains an important part of the conversation.

Learn more: https://heranova.com/

¹ American Society for Reproductive Medicine. “Endometriosis and Infertility: A Committee Opinion.” ASRM, 2012.
² Giudice, Linda C., et al. “Advances in Approaches to Diagnose Endometriosis.” Global Reproductive Health, vol. 9, no. 1, Spring 2024, e0074.
³ Liao, Liting, et al. “Endometriosis as a Risk Factor: Impact on IVF Outcomes and Reproductive Parameters: A Systematic Review and Meta‑Analysis.” Archives of Gynecology and Obstetrics, vol. 312, no. 4, 1 Aug. 2025, pp. 1085‑1093.

05/22/2026

In fertility care, one of the most important clinical questions is when surgical intervention may meaningfully influence outcomes.

HerResolve™, HerAnova's non-invasive blood test, is designed to help detect endometriosis and support more personalized decision-making across the fertility journey.

As James Kondrup, M.D., board-certified OB-GYN and minimally invasive gynecologic surgeon at CNY Fertility, shares:

"From a surgical perspective, the hardest question is not whether endometriosis exists, but whether operating at a given point in a patient's fertility journey will meaningfully change outcomes. HerResolve™ helps us better assess risk and personalize care. We use it to support surgical planning and align closely with our REI colleagues on when surgery should be considered prior to proceeding with the IVF process."

By delivering meaningful insight through a simple blood draw, HerResolve™ helps support risk assessment, interdisciplinary collaboration, and more personalized decision-making at pivotal moments in care.

05/19/2026

The HerAnova team is pleased to be invited to attend the 2026 Council of Physicians & Scientists (COPS) Annual Meeting hosted by US Fertility this week in San Diego.

This meeting brings together leaders across reproductive medicine to discuss the latest advances in fertility care, research, and innovation.

We're excited to connect with clinicians, scientists, and partners who share our commitment to advancing women's health and expanding access to non-invasive diagnostic solutions.

05/18/2026

At 41, one patient was preparing to move forward with embryo transfer, but with unexplained infertility and no definitive evidence of disease, timing was a priority. Given subtle signs that endometriosis might be a contributing factor, her physician incorporated HerResolve™ as part of a broader clinical evaluation before proceeding.

That additional molecular insight contributed to a broader conversation about timing and care planning prior to transfer, taking into account if endometriosis is detected. For patients in this situation, additional insight may help inform important fertility care decisions.

HerResolve™ is a blood-based test designed to support evaluation of endometriosis and contribute additional information when clinical questions remain.

Learn more: https://heranova.com/products/

05/15/2026

Innovation in women's health starts with addressing unmet needs through science.

HerResolve™ combines biomarker science and AI-driven analytics in a multiomic approach designed to support endometriosis detection.

By integrating qPCR and immunochemistry methodologies to assess specific microRNAs and proteins associated with endometriosis biology, HerResolve™ leverages machine learning and bioinformatics to advance a novel diagnostic approach in an area of significant unmet need.

At HerAnova, we're proud to help advance women's health through scientific innovation and solutions designed to address longstanding gaps in care.

Read our latest paper for more information: https://linkinghub.elsevier.com/retrieve/pii/S1553465026001512

05/13/2026

HerAnova's Chairwoman & Co-Founder, Penny Wan, was invited to join the SOHN Hong Kong Investment Conference for the Women in Finance Breakfast on May 20th.

Hosted by the Karen Leung Foundation - 梁愷昍婦癌基金會, this year's theme will focus on how investment can help accelerate innovation in women's health, an area that remains underfunded, despite significant global need.

We look forward to connecting with global investors and partners focused on addressing longstanding gaps in women's health, including endometriosis and fertility.

Click for more information: https://www.sohnconference.org/hong-kong

05/07/2026

Advancing how complex conditions like endometriosis are detected and diagnosed.

HerResolve™ is a non-invasive blood test designed to detect biological markers of endometriosis in women experiencing unexplained infertility or other symptoms suggestive of endometriosis such as pelvic pain or abnormal bleeding.

With just a simple blood draw, HerResolve™ can help support more informed conversations between physicians and patients around:
• Treatment decisions
• Family planning
• Surgical planning

By supporting more informed decision-making, we aim to reduce the uncertainty many women face in their diagnostic journey.

Learn more: https://heranova.com/products/

05/04/2026

HerAnova is honored to be selected once again to present at the 15th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2026) in Beijing, where our team and research collaborators will share research contributing to reproductive medicine.

With this year's theme, Journeying the Silk Road of Reproductive Care, the congress highlights the power of global collaboration and knowledge exchange to advance innovation in fertility and women's health.

Our Chief Medical Officer, Farideh Bischoff, PhD, alongside research collaborators, will be presenting our scientific findings on endometriosis and fertility. We look forward to engaging with clinicians, researchers, and innovators from around the world at this important meeting.

Check out more on the conference and program here: https://www.aspire2026.com/

04/27/2026

HerAnova Lifesciences attended the 23rd International Conference on Preimplantation Genetic Diagnosis (PGDIS 2026) in Shanghai, China this week.

Members of our leadership team, including our CMO, Farideh Bischoff, PhD, our CEO Jonathan Zhao, PhD, and the Chairman of our Scientific Advisory Board Dr. Joe Leigh Simpson connected with obstetricians, fertility specialists, embryologists, and human geneticists.

We were inspired by the discussions around innovation in reproductive health, endometriosis, and fertility.

04/24/2026

During , the connection between and comes into sharper focus, particularly at one of the most important decision points in a patient’s journey: timing.

For many women, the question is not just whether to proceed with IVF, but when and under what conditions. Symptoms like infertility, pelvic pain, and abnormal bleeding can signal underlying endometriosis, which may influence implantation, inflammation, and overall reproductive outcomes, even when not clearly visible on imaging.

This is where added biological insight can support an already thoughtful clinical approach.

At HerAnova, we are focused on bringing greater clarity into these moments. HerResolve™, our multi-omic, non-invasive blood test, is designed to detect endometriosis and help inform clinical strategy earlier in the fertility journey.

Because when it comes to IVF, timing and insight matter.

Learn more at HerAnova.com/products

Address

2 Burlington Woods Drive Suite 100
Burlington, MA
01803

Telephone

+18884891808

Website

http://heranova.com/

Alerts

Be the first to know and let us send you an email when HerAnova Lifesciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to HerAnova Lifesciences:

Shortcuts

Want your business to be the top-listed Health & Beauty Business in Burlington?